Robert B. Ford

Money Moves

Leading post-acquisition integration

Abbott Laboratories closed its $21 billion acquisition of Exact Sciences on March 23, making the maker of the Cologuard colorectal cancer screening test a wholly owned subsidiary of one of the world's largest healthcare companies. The all-cash deal, at $105 per share, passed through antitrust review without a second request from regulators—a sign of how little the two companies' product lines overlapped before this combination.

Updated Mar 23